Incyte Corporation reported first‑quarter 2026 results that surpassed analyst expectations, with revenue of $1.27 billion, up 21% year‑over‑year, and net income of $303 million. Basic earnings per share were $1.47, a $0.40 or 37% beat over the consensus estimate of $1.07. The company’s non‑GAAP diluted EPS of $1.81 also exceeded the $1.38–$1.40 consensus by $0.43–$0.41.
JAKAFI sales grew 7% to $758 million, while the ex‑Jakafi core business—comprising the Hematology and Oncology portfolio and Opzelura—generated $347 million in net sales, a 63% year‑over‑year increase. The broader Hematology and Oncology portfolio itself grew 116% to $204 million, reflecting strong demand for newer products. These segment gains drove the overall revenue growth and underscored the company’s successful diversification beyond its flagship drug.
"Our first quarter represented a strong start to 2026, driven by 20% year‑over‑year net sales growth and strong commercial execution," said CEO Bill Meury. "At the same time, we are making significant progress toward building a more durable, growth‑oriented portfolio with four anticipated product approvals and launches over the next 12 months, positive registrational data for povorcitinib in vitiligo and a late‑stage pipeline that now includes 10 Phase 3 studies underway, including the initiation of a pivotal trial of our G12D inhibitor in first‑line pancreatic ductal adenocarcinoma." Meury also noted, "Sales increased for every marketed product, both in the U.S. and internationally, and was driven by strong prescription and volume demand across the portfolio."
Management reaffirmed its full‑year 2026 guidance, projecting net sales of $4.77 billion to $4.94 billion and core business (ex‑JAKAFI) revenue of $1.57 billion to $1.69 billion. The guidance reflects confidence in sustained demand for the expanded portfolio and the pipeline’s expected commercial impact.
Operating expenses rose 14% in the quarter, while revenue increased 19%, improving operating leverage and contributing to margin expansion. The company’s cost‑control discipline and the higher mix of high‑margin products have helped maintain profitability despite the broader market’s competitive pressures.
Compared with Q1 2025, when revenue was $1.05 billion, net sales were $922 million, and diluted GAAP EPS was $0.80, the current quarter shows accelerated growth across all key metrics. The results demonstrate a clear trajectory toward the company’s long‑term goal of a diversified, growth‑oriented business model.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.